azacitidine has been researched along with verapamil in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Albert, DH; Bui, MH; Edalji, RP; Elmore, SW; Faivre, EJ; Fang, G; Fidanze, SD; Gao, W; Hasvold, LA; Huang, X; Hutchins, CW; Kati, WM; Li, L; Lin, X; Liu, D; Magoc, TJ; Mantei, RA; Martin, R; McDaniel, KF; Park, CH; Pratt, JK; Rajaraman, G; Shen, JJ; Shen, Y; Sheppard, GS; Soltwedel, T; Sun, CC; Wang, L; Wang, R; Warder, SE; Wilcox, D; Wong, S | 1 |
| Bekesi, G; Holland, JF; Richardson, EB; Silverman, LR; Zinzar, S | 1 |
| deSilva, M; El-Osta, A; Hu, XF; Kantharidis, P; Nadalin, G; Parkin, JD; Slater, A; Wall, DM; Zalcberg, JR | 1 |
| Aird, RE; Chen, H; Cummings, J; Jodrell, DI; Morris, RE; Muir, M; Ritchie, AA; Sadler, PJ | 1 |
| Barge, RM; Honders, MW; Spoelder, HE; Veuger, MJ; Willemze, R | 1 |
1 review(s) available for azacitidine and verapamil
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
9 other study(ies) available for azacitidine and verapamil
| Article | Year |
|---|---|
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.
Topics: Animals; Cell Line, Tumor; Chromatography, High Pressure Liquid; Drug Discovery; Fluorescence Resonance Energy Transfer; Half-Life; Humans; Mass Spectrometry; Mice; Proteins; Proton Magnetic Resonance Spectroscopy; Pyridones; Structure-Activity Relationship; Sulfonamides | 2017 |
Azacytidine plus verapamil induces the differentiation of a newly characterized biphenotypic human myeloid-B lymphoid leukemic cell line BW-90.
Topics: Azacitidine; Cell Differentiation; Drug Synergism; Growth Substances; Humans; Immunophenotyping; Leukemia, Myelomonocytic, Acute; Recombinant Proteins; Verapamil | 1998 |
Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance.
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Blotting, Southern; Daunorubicin; Decitabine; Dinucleoside Phosphates; DNA Methylation; Drug Resistance, Multiple; Epirubicin; Exons; Humans; Introns; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, T-Cell; Promoter Regions, Genetic; Restriction Mapping; Transcription, Genetic; Tumor Cells, Cultured; Verapamil | 1997 |
In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Calcium Channel Blockers; Carboplatin; Cisplatin; Decitabine; Drug Design; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Edetic Acid; Female; Humans; Ligands; Mice; Mice, Nude; Neoplasm Proteins; Organometallic Compounds; Ovarian Neoplasms; Ruthenium Compounds; Structure-Activity Relationship; Verapamil; Xenograft Model Antitumor Assays | 2002 |
Inactivation of deoxycytidine kinase and overexpression of P-glycoprotein in AraC and daunorubicin double resistant leukemic cell lines.
Topics: 2-Chloroadenosine; Alternative Splicing; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Biological Transport; Buthionine Sulfoximine; Calcium Channel Blockers; Cytarabine; Daunorubicin; Decitabine; Deoxyadenosines; Deoxycytidine Kinase; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glutathione; Humans; Idarubicin; Leukemia; Methotrexate; Neoplasm Proteins; Rats; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Verapamil | 2003 |